2-Methoxy-3-methylbutan-1-amine | 883541-50-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methoxy-3-methylbutan-1-amine
• CAS: 883541-50-2
• 化学式: C₆H₁₅NO
• mdl: MFCD06248009
• 分子量: 117.19
• InChiKey: ORBDGFSVVFALPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Azolylacylguanidines as beta-secretase inhibitors
  申请人：Cole Cecil Derek

  公开号：US20060183790A1

  公开（公告）日：2006-08-17

  The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

  本发明提供了一种化合物，其化学式为I。本发明还提供了利用该化合物抑制β-分泌酶(BACE)、治疗β-淀粉样沉积和神经原纤维缠结的方法。
• Pyridine derivatives as H3 antagonists
  申请人：Nettekoven Heinrich Matthias

  公开号：US20060122187A1

  公开（公告）日：2006-06-08

  The present invention relates to compounds of formula I wherein R 1 , R 2 and A are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及公式I中的化合物，其中R1、R2和A如描述和权利要求中定义，以及其药学上可接受的盐，以及包含这些化合物的药物组合物以及其制备方法。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS
  申请人：Cole Derek Cecil

  公开号：US20080287424A1

  公开（公告）日：2008-11-20

  The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

  本发明提供了一种式子为I的咪唑基酰基喹啉胺化合物。本发明还提供了使用该化合物的方法，以抑制β-分泌酶（BACE）并治疗β-淀粉样沉积和神经原纤维缠结。
• Novel benzazepine derivatives
  申请人：Glaxo Group Limited

  公开号：EP2133340A1

  公开（公告）日：2009-12-16

  The present invention relates to novel benzazepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. More specifically, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein formula (I) is as defined herein.

  本发明涉及具有药理活性的新型苯并氮杂卓衍生物、其制备工艺、含有它们的组合物以及它们在治疗神经和精神疾病中的用途。 更具体地说，本发明涉及式（I）化合物或其药学上可接受的盐： 其中式 (I) 如本文所定义。
• BENZAMIDE DERIVATIVES AS THROMBIN INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1021411A1

  公开（公告）日：2000-07-26